SHRX.V Sharp Therapeutics Corp.
- Market cap
- CAD 43.3M
- P/E
- -
- P/B
- 6.04x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is SHRX.V undervalued?
Graham numberThe Graham number of Sharp Therapeutics Corp. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sharp Therapeutics Corp. fundamental analysis
No fundamental analysis for Sharp Therapeutics Corp. yet.
Sharp Therapeutics Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sharp Therapeutics Corp.
Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies that allows the creation of sensitive assays mimicking the genetic disease state, enabling discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a custom-built, cloud-distributed analytics platform t…
Full company profileSharp Therapeutics Corp. financial statements
Sharp Therapeutics Corp. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Income Statement | |||
| Revenue | 0.00 | 0.00 | 0.00 |
| Operating Income | -2.27M | -4.55M | -5.51M |
| EBITDA | -3.28M | -2.99M | -5.91M |
| Net Income | -3.56M | -3.26M | -6.17M |
| EPS | -0.13 | -0.12 | -0.21 |
| Balance Sheet | |||
| Total Assets | 1.55M | 4.55M | 1.95M |
| Total Liabilities | 13.0M | 1.97M | 2.13M |
| Shareholders' Equity | -11.5M | 2.58M | -177K |
| Cash & Short-term Investments | 377K | 3.48M | 957K |
| Cash Flow | |||
| Operating Cash Flow | -1.96M | -3.62M | -4.83M |
| Capital Expenditure | 10.3K | 14.5K | 0.00 |
| Free Cash Flow | -1.97M | -3.63M | -4.83M |
| Ratios | |||
| ROE | - | -126.2% | - |
| ROA | -230.5% | -71.6% | -316.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Sharp Therapeutics Corp. dividends
Sharp Therapeutics Corp. has not paid dividends in the last 3 fiscal years.
Last stock split: 1:10 on Jan 27, 2025.
Who owns Sharp Therapeutics Corp.
- Insiders 42.49%
- Institutions 0.00%
- Public & others 57.52%
- Shares outstanding 31.6M
- Free float 17.6M
Sharp Therapeutics Corp. company profile
- Company name
- Sharp Therapeutics Corp.
- Ticker
- SHRX.V
- Exchange
- TSX Venture Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 2403 Sidney Street, Pittsburgh, PA, United States, 15203
- Phone
- 412 206 5303
- Website
- sharptx.com
About Sharp Therapeutics Corp.
Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies that allows the creation of sensitive assays mimicking the genetic disease state, enabling discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a custom-built, cloud-distributed analytics platform that captures data for AlloChem compounds in CoreX assays. Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania.
Sharp Therapeutics Corp. management
4- Dr. Scott F. Sneddon J.D., Ph.D.CEO, Chief Science Officer & Director · born 1963
- Mr. Edward Jonasson CA CPACFO & Corporate Secretary · born 1969
- Mr. Marcel P. Bruchez Ph.D.Scientific Co-Founder & CTO
- Dr. Alan S. Waggoner Ph.D.Scientific Co-Founder and Chief Architect